These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 39153490)

  • 1. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Diawara H; Healy SA; Mwakingwe-Omari A; Issiaka D; Diallo A; Traore S; Soumbounou IH; Gaoussou S; Zaidi I; Mahamar A; Attaher O; Fried M; Wylie BJ; Mohan R; Doan V; Doritchamou JYA; Dolo A; Morrison RD; Wang J; Hu Z; Rausch KM; Zeguime A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Dicko A; Duffy PE;
    Lancet Infect Dis; 2024 Dec; 24(12):1366-1382. PubMed ID: 39153490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.
    Sissoko MS; Healy SA; Katile A; Zaidi I; Hu Z; Kamate B; Samake Y; Sissoko K; Mwakingwe-Omari A; Lane J; Imeru A; Mohan R; Thera I; Guindo CO; Dolo A; Niare K; Koïta F; Niangaly A; Rausch KM; Zeguime A; Guindo MA; Bah A; Abebe Y; James ER; Manoj A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Doumbo O; Duffy PE
    Lancet Infect Dis; 2022 Mar; 22(3):377-389. PubMed ID: 34801112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.
    Sissoko MS; Healy SA; Katile A; Omaswa F; Zaidi I; Gabriel EE; Kamate B; Samake Y; Guindo MA; Dolo A; Niangaly A; Niaré K; Zeguime A; Sissoko K; Diallo H; Thera I; Ding K; Fay MP; O'Connell EM; Nutman TB; Wong-Madden S; Murshedkar T; Ruben AJ; Li M; Abebe Y; Manoj A; Gunasekera A; Chakravarty S; Sim BKL; Billingsley PF; James ER; Walther M; Richie TL; Hoffman SL; Doumbo O; Duffy PE
    Lancet Infect Dis; 2017 May; 17(5):498-509. PubMed ID: 28216244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial.
    Coulibaly D; Kone AK; Traore K; Niangaly A; Kouriba B; Arama C; Zeguime A; Dolo A; Lyke KE; Plowe CV; Abebe Y; Potter GE; Kennedy JK; Galbiati SM; Nomicos E; Deye GA; Richie TL; James ER; Kc N; Sim BKL; Hoffman SL; Doumbo OK; Thera MA; Laurens MB;
    EClinicalMedicine; 2022 Oct; 52():101579. PubMed ID: 35928033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial.
    González R; Nhampossa T; Mombo-Ngoma G; Mischlinger J; Esen M; Tchouatieu AM; Mendes A; Figueroa-Romero A; Zoleko-Manego R; Lell B; Lagler H; Stoeger L; Dimessa LB; El Gaaloul M; Sanz S; Méndez S; Piqueras M; Sevene E; Ramharter M; Saúte F; Menendez C;
    Lancet Infect Dis; 2024 May; 24(5):476-487. PubMed ID: 38224706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands.
    van der Plas JL; Kuiper VP; Bagchus WM; Bödding M; Yalkinoglu Ö; Tappert A; Seitzinger A; Spangenberg T; Bezuidenhout D; Wilkins J; Oeuvray C; Dhingra SK; Thathy V; Fidock DA; Smidt LCA; Roozen GVT; Koopman JPR; Lamers OAC; Sijtsma J; van Schuijlenburg R; Wessels E; Meij P; Kamerling IMC; Roestenberg M; Khandelwal A
    Lancet Infect Dis; 2023 Oct; 23(10):1164-1174. PubMed ID: 37414066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial.
    Barsosio HC; Madanitsa M; Ondieki ED; Dodd J; Onyango ED; Otieno K; Wang D; Hill J; Mwapasa V; Phiri KS; Maleta K; Taegtmeyer M; Kariuki S; Schmiegelow C; Gutman JR; Ter Kuile FO
    Lancet; 2024 Jan; 403(10424):365-378. PubMed ID: 38224710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Pilot Trial to Evaluate
    Noudjiegbe AN; Alikekere FN; Tchehouenou H; Langa Y; Ota DS; Degbelo JE; Allabi ACE
    Evid Based Complement Alternat Med; 2020; 2020():8715021. PubMed ID: 32215047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial.
    Tripura R; von Seidlein L; Sovannaroth S; Peto TJ; Callery JJ; Sokha M; Ean M; Heng C; Conradis-Jansen F; Madmanee W; Peerawaranun P; Waithira N; Khonputsa P; Jongdeepaisal M; Pongsoipetch K; Chotthanawathit P; Soviet U; Pell C; Duanguppama J; Rekol H; Tarning J; Imwong M; Mukaka M; White NJ; Dondorp AM; Maude RJ
    Lancet Infect Dis; 2023 Jan; 23(1):81-90. PubMed ID: 36174595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.
    Sagara I; Healy SA; Assadou MH; Gabriel EE; Kone M; Sissoko K; Tembine I; Guindo MA; Doucoure M; Niaré K; Dolo A; Rausch KM; Narum DL; Jones DL; MacDonald NJ; Zhu D; Mohan R; Muratova O; Baber I; Coulibaly MB; Fay MP; Anderson C; Wu Y; Traore SF; Doumbo OK; Duffy PE
    Lancet Infect Dis; 2018 Sep; 18(9):969-982. PubMed ID: 30061051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
    Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
    Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.
    Sulyok M; Rückle T; Roth A; Mürbeth RE; Chalon S; Kerr N; Samec SS; Gobeau N; Calle CL; Ibáñez J; Sulyok Z; Held J; Gebru T; Granados P; Brückner S; Nguetse C; Mengue J; Lalremruata A; Sim BKL; Hoffman SL; Möhrle JJ; Kremsner PG; Mordmüller B
    Lancet Infect Dis; 2017 Jun; 17(6):636-644. PubMed ID: 28363637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective efficacy and safety of radiation-attenuated and chemo-attenuated Plasmodium Falciparum sporozoite vaccines against controlled and natural malaria infection: a systematic review and meta-analysis of randomized controlled trials.
    Abuelazm MT; Elzeftawy MA; Kamal MA; Badr H; Gamal M; Aboulgheit M; Abdelazeem B; Abd-Elsalam S; Abouzid M
    Infection; 2024 Jun; 52(3):707-722. PubMed ID: 38319556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
    Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ;
    Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.
    McCarthy JS; Yalkinoglu Ö; Odedra A; Webster R; Oeuvray C; Tappert A; Bezuidenhout D; Giddins MJ; Dhingra SK; Fidock DA; Marquart L; Webb L; Yin X; Khandelwal A; Bagchus WM
    Lancet Infect Dis; 2021 Dec; 21(12):1713-1724. PubMed ID: 34715032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.
    Oneko M; Steinhardt LC; Yego R; Wiegand RE; Swanson PA; Kc N; Akach D; Sang T; Gutman JR; Nzuu EL; Dungani A; Kim Lee Sim B; Oloo PN; Otieno K; Bii DK; Billingsley PF; James ER; Kariuki S; Samuels AM; Jongo S; Chebore W; Abdulla S; Daubenberger C; Mpina M; Styers D; Potter GE; Abarbanell G; Richie TL; Hoffman SL; Seder RA
    Nat Med; 2021 Sep; 27(9):1636-1645. PubMed ID: 34518679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
    Hamaluba M; van der Pluijm RW; Weya J; Njuguna P; Ngama M; Kalume P; Mwambingu G; Ngetsa C; Wambua J; Boga M; Mturi N; Lal AA; Khuroo A; Taylor WRJ; Gonçalves S; Miotto O; Dhorda M; Mutinda B; Mukaka M; Waithira N; Hoglund RM; Imwong M; Tarning J; Day NPJ; White NJ; Bejon P; Dondorp AM
    Lancet Infect Dis; 2021 Oct; 21(10):1395-1406. PubMed ID: 34111412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial.
    Stephenson KE; Tan CS; Walsh SR; Hale A; Ansel JL; Kanjilal DG; Jaegle K; Peter L; Borducchi EN; Nkolola JP; Makoni T; Fogel R; Bradshaw C; Tyler A; Moseley E; Chandrashekar A; Yanosick KE; Seaman MS; Eckels KH; De La Barrera RA; Thompson J; Dawson P; Thomas SJ; Michael NL; Modjarrad K; Barouch DH
    Lancet Infect Dis; 2020 Sep; 20(9):1061-1070. PubMed ID: 32618279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.